This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sève, P. Articles by Dumontet, C. Search for Related Content PubMed PubMed Citation Articles by Sève, P. Articles by Dumontet, C.

¹ Service de Médecine Interne, Hospices Civils de Lyon; ² Unité Institut National de la Sante et de la Recherche Medicale 590, Laboratoire de Cytologie Analytique, Université Claude Bernard; ³ Service de Pneumologie, Hôpital de la Croix-Rousse; ⁴ Laboratoire d'Immunologie des Hémopathies, Hôpital Edouard-Herriot, Lyon, France; Departments of ⁵ Oncology and ⁶ Pathology, University of Alberta, Edmonton, Alberta, Canada; ⁷ Laboratoire d'Anatomopathologie and ⁸ Service de Pneumologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; and ⁹ Polyclinique de Rillieux, Rillieux, France

Requests for reprints: Charles Dumontet, Unité Institut National de la Sante et de la Recherche Medicale 590, Laboratoire de Cytologie Analytique, Faculté de Médecine, Université Claude Bernard, 8 Avenue Rockefeller, 69373 Lyon Cedex 08, France. Phone: 33-4-78-77-72-36. E-mail: charles.dumontet{at}chu-lyon.fr

Both fundamental and clinical studies suggest that class III ß-tubulin expression is associated with resistance to taxanes and constitutes a prognostic factor in several solid tumors. In this study, we assessed the prognostic and predictive value of class III ß-tubulin in tumors of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with paclitaxel-based or other regimens that did not include tubulin-binding agents. Expression of class III ß-tubulin was examined immunohistochemically in 91 tumor samples obtained before treatment from patients with stage III and IV NSCLC, including 47 who received paclitaxel-based regimens and 44 who received regimens without tubulin-binding agents. Response to chemotherapy, progression-free survival, and overall survival were correlated with the expression of class III ß-tubulin protein. The response rate was 37.5% (16 responses among 45 evaluable patients) among patients receiving paclitaxel. Patients whose tumors expressed low levels of class III ß-tubulin isotype had a better response rate, longer progression-free survival, and overall survival (P < 0.001, 0.004, and 0.002, respectively), whereas this variable was not found to be predictive in patients receiving regimens without tubulin-binding agents. A multivariate analysis taking into account sex, age, histology, stage, and class III ß-tubulin confirmed that low-level class III ß-tubulin expression was independently correlated with progression-free survival (P = 0.003) and overall survival (P = 0.003). These findings suggest that the expression levels of class III ß-tubulin in tumor cells is predictive of response to therapy and patient outcome in patients with NSCLC receiving paclitaxel-based chemotherapy but is not a general prognostic factor in this patient population. [Mol Cancer Ther 2005;4(12):2001–7]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/14/05; revised 8/24/05; accepted 9/27/05.

This article has been cited by other articles:

				A.-M. Liberatore, H. Coulomb, D. Pons, O. Dutruel, P. G. Kasprzyk, M. Carlson, A. S. Nelson, S. P. Newman, C. Stengel, P. Auvray, et al. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents Mol. Cancer Ther., August 1, 2008; 7(8): 2426 - 2434. [Abstract] [Full Text] [PDF]

				C. M. Galmarini, I. Treilleux, F. Cardoso, C. Bernard-Marty, V. Durbecq, D. Gancberg, M.-C. Bissery, M. Paesmans, D. Larsimont, M. J. Piccart, et al. Class III {beta}-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel Clin. Cancer Res., July 15, 2008; 14(14): 4511 - 4516. [Abstract] [Full Text] [PDF]

				S. H. Hwang, A. Rait, K. F. Pirollo, Q. Zhou, V. M. Yenugonda, G. M. Chinigo, M. L. Brown, and E. H. Chang Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue Mol. Cancer Ther., March 1, 2008; 7(3): 559 - 568. [Abstract] [Full Text] [PDF]

				L. Vahdat Ixabepilone: A Novel Antineoplastic Agent with Low Susceptibility to Multiple Tumor Resistance Mechanisms Oncologist, March 1, 2008; 13(3): 214 - 221. [Abstract] [Full Text] [PDF]

				A. Jimeno, G. Hallur, A. Chan, X. Zhang, G. Cusatis, F. Chan, P. Shah, R. Chen, E. Hamel, E. Garrett-Mayer, et al. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer Mol. Cancer Ther., May 1, 2007; 6(5): 1509 - 1516. [Abstract] [Full Text] [PDF]

				R. van Amerongen and A. Berns TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes & Dev., August 1, 2006; 20(15): 1975 - 1981. [Full Text] [PDF]